PMID- 23006540
OWN - NLM
STAT- MEDLINE
DCOM- 20130410
LR  - 20220330
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
VI  - 28
IP  - 4
DP  - 2012 Oct
TI  - Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in 
      type 2 diabetes patients in China.
PG  - 436-44
LID - 10.1017/S0266462312000608 [doi]
AB  - OBJECTIVES: The aim of this study was to evaluate the long-term cost-utility of 
      liraglutide versus glimepiride as add-on therapy to metformin in patients with 
      type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted 
      in Asian population. METHODS: The validated UKPDS Outcomes Model was used to 
      project life expectancy, quality adjusted life-years (QALYs), incidence of 
      diabetes-related complication and cost of complications in patients receiving 
      those regimens. Baseline cohort characteristics and treatment effects were 
      derived from an Asian study. China-specific complication costs and utility score 
      were taken from local studies. Patients' outcomes were modeled for 30 years and 
      incremental cost-effectiveness ratios were calculated for liraglutide compared 
      with glimepiride from the healthcare system perspective. Both future costs and 
      clinical benefits were discounted at 3 percent. Sensitivity analyses were 
      performed. RESULTS: Over a period of 30 years, compared with glimepiride, 
      liraglutide 1.8 mg was associated with improvements in life expectancy (0.1 year) 
      and quality adjusted life-year (0.168 QALY), and a reduced incidence of 
      diabetes-related complications leading to an incremental cost-effectiveness ratio 
      per QALY gained versus glimepiride of CNY 25,6871 (DEC 2010, 1 USD = 6.6227 CNY). 
      CONCLUSIONS: Long-term projections indicated that liraglutide was associated with 
      increased life expectancy, QALYs, and reduced complication incidences comparing 
      with glimepiride. When the UK cost of liraglutide was discounted by 38 percent, 
      liraglutide would be a cost-effective option in China from the healthcare system 
      perspective using the 3X GDP/capita per QALY as the WTP threshold.
FAU - Gao, Lan
AU  - Gao L
AD  - School of Biomedical Sciences & Pharmacy, University of Newcastle, Australia.
FAU - Zhao, Fei-Li
AU  - Zhao FL
FAU - Li, Shu-Chuen
AU  - Li SC
LA  - eng
PT  - Journal Article
DEP - 20120924
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 6KY687524K (glimepiride)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - China
MH  - Confidence Intervals
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/economics
MH  - Drug Therapy, Combination
MH  - Glucagon-Like Peptide 1/*analogs & derivatives/economics/therapeutic use
MH  - Health Care Costs
MH  - Humans
MH  - Hypoglycemic Agents/economics/*therapeutic use
MH  - Life Expectancy
MH  - Liraglutide
MH  - Metformin/economics/*therapeutic use
MH  - Models, Economic
MH  - Quality-Adjusted Life Years
MH  - Sulfonylurea Compounds/economics/*therapeutic use
EDAT- 2012/09/26 06:00
MHDA- 2013/04/11 06:00
CRDT- 2012/09/26 06:00
PHST- 2012/09/26 06:00 [entrez]
PHST- 2012/09/26 06:00 [pubmed]
PHST- 2013/04/11 06:00 [medline]
AID - S0266462312000608 [pii]
AID - 10.1017/S0266462312000608 [doi]
PST - ppublish
SO  - Int J Technol Assess Health Care. 2012 Oct;28(4):436-44. doi: 
      10.1017/S0266462312000608. Epub 2012 Sep 24.